## **Supplementary Materials**

## Identification of a specific binding peptide to boron nitride nanospheres for the intracellular delivery of CpG oligodeoxynucleotides

Huijie Zhang<sup>a,b</sup>, Tomohiko Yamazaki<sup>a,b</sup>, Chunyi Zhi<sup>b</sup>, and Nobutaka Hanagata<sup>a,b,c\*</sup>

<sup>a</sup>Graduate School of Life Science, Hokkaido University, N10W8, Kita-ku, Sapporo, 060-0812, Japan

<sup>b</sup>Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), National Institute for Materials Science (NIMS), 1-2-1 Sengen, Tsukuba, Ibaraki 305-0047, Japan

<sup>c</sup>Nanotechnology Innovation Station, NIMS, 1-2-1 Sengen, Tsukuba, Ibaraki 305-0047, Japan

<sup>\*</sup>To whom correspondence should be addressed. Nanotechnology Innovation Station, National Institute for Materials Science, 1-2-1 Sengen, Tsukuba, Ibaraki 305-0047, Japan; E-mail: HANAGATA.Nobutaka@nims.go.jp; Tel: +81-29-860-4774; Fax: +81-29-859-2475

## **Figure Legends**

**Supplementary Figure 1.** Yield (output phages /input phages) against the rounds of panning. The phages with higher affinity for BNNS had been successfully concentrated in the phage pool.

**Supplementary Figure 2.** Amino acid frequencies in the BNNS-binding peptide sequence, as compared to the original phage library.

**Supplementary Figure 3.** Fluorescence microscopy images of the FITC-labeled peptides binding to BNNS. In the control group, the BNNS were incubated without peptides.

**Supplementary Figure 4.** Fluorescence emission spectra of BNNS, BP7 and BNNS/BP7 complex in TBS buffer.

**Supplementary Figure 5.** Cytotoxicity, cell uptake of the BNNS/BP7 complexs to HEK293XL-null and Hela cells. (a) Viabilities of 293XL-null and Hela cells measured by a water-soluble tetrazolium salt assay against BNNS and BNNS/BP7 complexes. Concentrations of the nanospheres:  $0 \ \mu g/mL$  (Red),  $25 \ \mu g/mL$  (Cyan),  $50 \ \mu g/mL$  (Blue),  $75 \ \mu g/mL$  (Olive),  $100 \ \mu g/mL$  (Yellow). (b) Confocal microscopy images of HEK293XL-null and Hela cells after 24 h of incubation with BNNS/BP7 complexes. Data presented as mean  $\pm$  SD (n =5)

Supplementary Figure 6. Loading capacity of the BP7 mutants–CpG ODN conjugate on BNNS, denoted as  $\mu$ g CpG ODNs loaded on 1 mg BNNS. M1 (BP7-Y8A) and M2 (BP7-L10A) are mutants of BP7 whose tyrosine (Y8) and leucine (L10) at eighth and tenth positions from N-terminal were replaced by alanine (A), respectively. Loading capacity of the BP7–CpG ODN conjugate on BNNS is shown in Fig. 6a. Data presented as mean  $\pm$  SD (n = 3).

**Supplementary Figure 7.** Zeta potentials of BNNS, BNNS/BP7, BNNS/CpG ODNs, BNNS/BP7-CpG ODNs complexs in TBS buffer (pH 7.4). Data presented as mean ± SD (n =6)

**Supplementary Figure 8.** IFN- $\alpha$  induction from PBMCs stimulated by CpG ODNs. M1 (BP7-Y8A), M2 (BP7-L10A). The concentration of the BNNS was about  $87\mu$ g/mL. PTO-2216 is positive control. Data presented as mean  $\pm$  SD (n =3). The symbol # means not detectable (below detection limit).

**Supplementary Figure 9.** Cytokine induction from PBMCs stimulated by BP7 mutants–CpG ODN conjugate–loaded BNNS. (a) IL-6 production. (b) TNF- $\alpha$  production. Loaded BNNS (87  $\mu$ g/mL) was incubated with PBMCs for 8 h (TNF- $\alpha$ ) and 24 h (IL-6) respectively, M1 (BP7-Y8A) and M2 (BP7-L10A) are mutants of BP7 whose tyrosine (Y8) and leucine (L10) at eighth and tenth positions from N-terminal were replaced by alanine (A), respectively. The levels of IL-6

and TNF- $\alpha$  induced by BNNS/BP7-CpG ODNs are shown in Fig. 7. Data are presented as mean  $\pm$  SD (n = 3).



**Supplementary Figure 1.** Yield (output phages /input phages) against the rounds of panning. The phages with higher affinity for BNNS had been successfully concentrated in the phage pool.



**Supplementary Figure 2.** Amino acid frequencies in the BNNS-binding peptide sequence, as compared to the original phage library.

| BP1 | BP2 | BP3     |
|-----|-----|---------|
| BP4 | BP5 | BP6     |
| BP7 | BPS | Control |

**Supplementary Figure 3.** Fluorescence microscopy images of the FITC-labeled peptides binding to BNNS. In the control group, the BNNS were incubated without peptides.



**Supplementary Figure 4.** Fluorescence emission spectra of BNNS, BP7 and BNNS/BP7 complex in TBS buffer.



**Supplementary Figure 5.** Cytotoxicity, cell uptake of the BNNS/BP7 complexs to HEK293XL-null and Hela cells. (a) Viabilities of HEK293XL-null and Hela cells measured by a water-soluble tetrazolium salt assay for BNNS and BNNS/BP7 complexes. Concentrations of the nanospheres: 0  $\mu$ g/mL (Red), 25 $\mu$ g/mL (Cyan), 50 $\mu$ g/mL (Blue), 75 $\mu$ g/mL (Olive), 100 $\mu$ g/mL (Yellow). (b) Confocal microscopy images of HEK293XL-null and Hela cells after 24 h of incubation with BNNS/BP7 complexes. Data presented as mean  $\pm$  SD (n =5).



Supplementary Figure 6. Loading capacity of the BP7 mutants–CpG ODN conjugate on BNNS, denoted as  $\mu$ g CpG ODNs loaded on 1 mg BNNS. M1 (BP7-Y8A) and M2 (BP7-L10A) are mutants of BP7 whose tyrosine (Y8) and leucine (L10) at eighth and tenth positions from N-terminal were replaced by alanine (A), respectively. Loading capacity of the BP7–CpG ODN conjugate on BNNS is shown in Fig. 6a. Data presented as mean  $\pm$  SD (n = 3).



**Supplementary Figure 7.** Zeta potentials of BNNS, BNNS/BP7, BNNS/CpG ODNs, BNNS/BP7-CpG ODNs complexs in TBS buffer (pH 7.4). Data presented as mean  $\pm$  SD (n =6).



**Supplementary Figure 8.** IFN- $\alpha$  induction from PBMCs stimulated by CpG ODNs. M1 (BP7-Y8A) and M2 (BP7-L10A) are mutants of BP7 whose tyrosine (Y8) and leucine (L10) at eighth and tenth positions from N-terminal were replaced by alanine (A), respectively. The concentration of the BNNS was about 87µg/mL. PTO-2216 is positive control. Data presented as mean ± SD (n =3). The symbol # means not detectable (below detection limit).



**Supplementary Figure 9.** Cytokine induction from PBMCs stimulated by BP7 mutants–CpG ODN conjugate–loaded BNNS. (a) IL-6 production. (b) TNF- $\alpha$  production. Loaded BNNS (87  $\mu$ g/mL) was incubated with PBMCs for 8 h (TNF- $\alpha$ ) and 24 h (IL-6) respectively, M1 (BP7-Y8A) and M2 (BP7-L10A) are mutants of BP7 whose tyrosine (Y8) and leucine (L10) at eighth and tenth positions from N-terminal were replaced by alanine (A), respectively. The levels of IL-6 and TNF- $\alpha$  induced by BNNS/BP7-CpG ODNs are shown in Fig. 7. Data are presented as mean  $\pm$  SD (n = 3).